Single agent lorigerlimab demonstrated encouraging preliminary clinical activity in clear cell gynecologic cancer (CCGC) with a confirmed ORR of ...

A retrospective single-center cohort of 128 patients associated frontline bevacizumab with longer overall survival in ...

Amplia Therapeutics has advanced its cancer drug narmafotinib across four trials, with data suggesting it may work independently of common tumour-causing KRAS gene mutations.

Data Update demonstrates significant clinical benefit and survival improvements in advanced, chemoresistant sarcomas, ...

ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor ...

An AI model created by researchers at King's can detect signs of faulty repair mechanisms in ovarian cancer cells, potentially leading to a low-cost, widely accessible diagnostic tool in the future.

A multi-omics study combining genomics and spatial transcriptomics finds that BRCA-mutated high-grade serous ovarian cancers show stronger interferon and inflammatory programs within shared ...

HRDPath, an AI model, analyzes tissue images to identify ovarian cancers with homologous recombination deficiency.

BioInvent reported updated Phase 1/2 data from Part B of its ongoing study of BI-1808 combined with pembrolizumab in heavily pretreated, platinum-resistant recurrent ovarian cancer, showing a 24% ...

Single-cell profiling at diagnosis can identify which patients with an aggressive form of ovarian cancer are likely to ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase ...

The investigational folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC) sofetabart mipitecan (LY4170156) ...